Edition:
United States

PLx Pharma Inc (PLXP.OQ)

PLXP.OQ on NASDAQ Stock Exchange Capital Market

7.00USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$7.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,599
52-wk High
$21.60
52-wk Low
$5.60

Latest Key Developments (Source: Significant Developments)

Park West Asset Management reports 12.3 pct stake in PLx Pharma
Monday, 20 Nov 2017 05:42pm EST 

Nov 20 (Reuters) - Park West Asset Management Llc::Park West Asset Management Llc reports 12.3 percent stake in PLx Pharma Inc ‍​as of November 20 - SEC filing.Park West Asset Management-anticipates engaging in discussions with PLx Pharma management,members of board concerning potential financing transactions.  Full Article

PLx Pharma Inc. Reports third quarter 2017 results
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Plx Pharma Inc :PLx Pharma Inc. reports third quarter 2017 results.Q3 loss per share $0.44.  Full Article

PLx Pharma reports Q2 loss per share $0.36
Thursday, 10 Aug 2017 04:30pm EDT 

Aug 10 (Reuters) - PLx Pharma Inc -:PLx Pharma Inc teports second quarter 2017 results.Q2 loss per share $0.36.  Full Article

PLX Pharma announces pricing of registered direct offering
Monday, 12 Jun 2017 06:50am EDT 

June 12 (Reuters) - Plx Pharma Inc :PLX Pharma announces pricing of registered direct offering.To use net proceeds from this offering, together with current cash resources, to advance aspertec 325 mg to market-readiness.Pricing of registered direct offering of 2.65 million shares of common stock at an offering price per share of $6.875.Also to use proceeds from offering, together with current cash resources, to fund technology transfer, commercial scale validation, manufacturing.  Full Article

Rita O'Connor appointed CFO of PLx Pharma
Tuesday, 2 May 2017 07:00am EDT 

May 2 (Reuters) - Plx Pharma Inc :Rita m. o’connor appointed chief financial officer of plx pharma.Plx pharma inc - o'connor succeeds david jorden, who has served as company's acting cfo since june 2015.Plx pharma inc - jorden will transition at end of july.  Full Article

Dipexium and PLX Pharma announce merger agreement
Thursday, 22 Dec 2016 04:39pm EST 

Dipexium Pharmaceuticals Inc : Dipexium Pharmaceuticals -following closing, dipexium will be renamed PLX Pharma Inc, and will operate under leadership of PLX management team . Dipexium Pharmaceuticals Inc - co to issue about 36 million new shares of common stock to PLX stockholders under exchange ratio formula . Dipexium Pharmaceuticals Inc - boards of directors of both Dipexium and PLX Pharma have unanimously approved proposed transaction . Dipexium Pharmaceuticals Inc - PLX stockholders will receive newly issued shares of common stock of Dipexium . Dipexium and PLX Pharma announce merger agreement . Dipexium Pharmaceuticals Inc - upon closing of merger, existing PLX stockholders are expected to own 76.75% of Dipexium common shares outstanding . Dipexium Pharmaceuticals Inc - Michael Valentino to serve as executive chairman of board and Natasha Giordano to serve as president and CEO of combined co . Dipexium Pharmaceuticals Inc - upon closing of merger, existing Dipexium stockholders are expected to own 23.25% of Dipexium common shares outstanding . Dipexium Pharmaceuticals Inc -upon closing the merger, existing PLX stockholders are expected to own 76.75% of Dipexium common shares outstanding .Dipexium and PLX Pharma announce merger agreement.  Full Article

Dipexium announces top-line data from onestep phase 3 trials
Tuesday, 25 Oct 2016 07:00am EDT 

Dipexium Pharmaceuticals Inc : Announces top-line data from onestep phase 3 trials with locilex in mild diabetic foot infection did not meet primary clinical endpoint of superiority versus vehicle plus standardized wound care . Top-line data from onestep phase 3 trials with locilex in mild diabetic foot infection did not meet primary clinical endpoint .Serious adverse events with locilex included higher than anticipated osteomyelitis and cellulitis in locilex arm of each study.  Full Article

Dipexium Pharmaceuticals Q2 loss per share $0.52
Thursday, 4 Aug 2016 07:00am EDT 

Dipexium Pharmaceuticals Inc : Dipexium Pharmaceuticals reports second quarter 2016 financial results . Q2 loss per share $0.52 .Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.  Full Article

Dipexium pharmaceuticals posts Q1 loss per share $0.56
Thursday, 12 May 2016 10:40am EDT 

Dipexium Pharmaceuticals Inc : Announces Completion Of Enrollment Objective In Onestep 2 pivotal phase 3 clinical trial and first quarter 2016 financial results . Dipexium Pharmaceuticals Inc qtrly loss per share $0.56 . Company's cash balance is currently anticipated to fund operations through 2017 .Line data from pivotal phase 3 clinical trials in q3 of 2016.  Full Article

BRIEF-Park West Asset Management reports 12.3 pct stake in PLx Pharma

* Park West Asset Management Llc reports 12.3 percent stake in PLx Pharma Inc ‍​as of November 20 - SEC filing